Módszerek összehasonlítása

	Acne-QoL (Acne Quality of Life Scale)	Gyermekek Bőrtünetek Életminőség Indexe (cDLQI)	MelasQoL (Melasma Életminőség Skála)
Tudományterület	Bőrgyógyászat	Bőrgyógyászat	Bőrgyógyászat
Módszercsalád	Process / pipeline	Process / pipeline	Process / pipeline
Keletkezés éve	2004	1995	2006
Megalkotó	Halvorsen JA et al.	Lewis-Jones MS, Finlay AY	Cestari TF, Hexsel D
Típus	Self-report	Self-report (parent or child proxy)	Self-report
Alapmű	Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011;131(2):363-370.	Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (cDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942-949.	Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20.
Alternatív nevek	Acne-Q, Acne-Specific QoL	cDLQI, Pediatric DLQI	Melasma-QoL
Kapcsolódó	4	3	3
Összefoglaló	Acne-QoL is a disease-specific, patient-administered quality-of-life measure assessing the psychological and social burden of acne vulgaris. Acne is the most common skin disease in adolescents and young adults and causes substantial psychological distress, depression, anxiety, and social impairment disproportionate to its severity. Multiple versions of Acne-QoL exist (19–24 items); all capture emotional, social, and functional impacts. Acne-QoL is essential in clinical trials and observational studies to ensure treatment efficacy encompasses quality-of-life outcomes.	The Children's Dermatology Life Quality Index (cDLQI) is a pediatric-adapted version of the adult DLQI, measuring the impact of skin disease on quality of life in children and adolescents aged 4–16 years. Developed by Lewis-Jones and Finlay in 1995, it uses child-friendly language and addresses domains relevant to childhood (school, leisure, friendships, clothing) rather than work and adult relationships. cDLQI is the standard quality-of-life measure in pediatric dermatology trials and clinical practice.	MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes.